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Primary cilia are microtubule-based organelles that
detect mechanical and chemical stimuli. Although
cilia house a number of oncogenic molecules
(including Smoothened, KRAS, EGFR, and PDGFR),
their precise role in cancer remains unclear. We
have interrogated the role of cilia in acquired and
de novo resistance to a variety of kinase inhibitors,
and found that, in several examples, resistant cells
are distinctly characterized by an increase in the
number and/or length of cilia with altered structural
features. Changes in ciliation seem to be linked to
differences in the molecular composition of cilia
and result in enhanced Hedgehog pathway activa-
tion. Notably, manipulating cilia length via Kif7
knockdown is sufficient to confer drug resistance in
drug-sensitive cells. Conversely, targeting of cilia
length or integrity through genetic and pharmacolog-
ical approaches overcomes kinase inhibitor resis-
tance. Our work establishes a role for ciliogenesis
and cilia length in promoting cancer drug resistance
and has significant translational implications.
INTRODUCTION
Primary cilia are microtubule-based sensory organelles that
detect mechanical and chemical stimuli, and are formed by
nearly all vertebrate cells (Garcia-Gonzalo and Reiter, 2012).
These antenna-like organelles house a number of oncogenic
molecules including Smoothened, KRAS (Lauth et al., 2010),
epidermal growth factor receptor (EGFR), and platelet-derived
growth factor receptor (PDGFR) (reviewed in Christensen et al.,
2012). Although loss of cilia has been associated with the onset
of malignancy in some human tumors (reviewed in Basten and
Giles, 2013), in others, cilia appear to be necessary for cancer3042 Cell Reports 23, 3042–3055, June 5, 2018 ª 2018 The Authors.
This is an open access article under the CC BY license (http://creativecell survival (Han et al., 2009; Wong et al., 2009; Li et al.,
2016). In fact, depending on the nature of the driver oncogenic
lesion, cilia can have opposing roles in tumorigenesis even in
the same tumor type. For example, removal of cilia inhibited
tumor growth in a mouse model of medulloblastoma (MB)
driven by constitutively active Smoothened (SMO). However,
cilia depletion in a GLI2-driven model of MB accelerated tumor
growth (Han et al., 2009). Therefore, the role of cilia in cancer re-
mains unclear and is likely to be context dependent. Further-
more, characterization of primary cilia in glioblastoma cells sug-
gests that cancer-associated cilia may be structurally distinct
(Moser et al., 2009; Sarkisian et al., 2014; Moser et al., 2014).
A number of cancer drugs inhibit proteins that have been
shown to localize to cilia, such as EGFR and PDGFR (Christen-
sen et al., 2012). These drugs (e.g., the EGFR inhibitor erlotinib)
promote significant tumor regressions in appropriate patient
populations (e.g., EGFR mutant non-small cell lung carcinoma
patients). However, these responses are invariably followed by
the emergence of lethal drug-resistant disease. Our understand-
ing of the molecular mechanisms of drug resistance has facili-
tated the design and deployment of second-line therapies that
can target drug-resistant tumors (Awada et al., 2015). However,
the characterization of thesemechanisms (particularly those that
do not involve mutation of the drug target itself) has been limited,
and specific to the individual target or drug. Thus, drug resis-
tance remains the main obstacle in delivering long-lasting thera-
peutic benefit. The identification of cell biological processes that
facilitate and support the emergence of drug resistancemay pro-
vide new therapeutic opportunities with broad applicability.
In this study, we report that the number and length of primary
cilia are upregulatedboth indenovoandacquired kinase inhibitor
resistance (KIR). These changes are associated with distinct mo-
lecular and structural features at the cilium, including (1) failure to
control cilia length, (2) increased Hedgehog pathway activation,
and (3) cilia fragmentation. Cilia elongation via Kif7 knockdown
is sufficient to increase survival in the presence of kinase inhibi-
tors, thus suggesting that cilia elongation has a critical role in pro-
moting drug resistance. Conversely, pharmacological targetingcommons.org/licenses/by/4.0/).
Figure 1. Acquired Resistance to Kinase Inhibitors in Human Cancer Cell Lines Is Associated with Increased Cilia Frequency, Cilia Length,
and Cilia Tip Fragmentation
(A) Control (left panels) or erlotinib-resistant (ErloR) (right panels) HCC4006 lung adenocarcinoma cells were serum starved for 48 hr to induce ciliogenesis, then
fixed and stained with antibodies for acetylated tubulin (green) and Arl13B (red) to mark cilia, g-tubulin (blue/inset) for centrioles, and DAPI (blue) to mark DNA.
Note that primary cilia are absent in parental HCC4006 cells but are present in the erlotinib-resistant subline.
(B) Quantification of experiment shown in (A). n = 300. Error bars represent SD. p < 0.005, unpaired t test.
(C) Parental (left panels) or NVP-TAE684 (NVP-TAE)-resistant (right panels) NCI-H2228 lung adenocarcinoma cells were serum starved for 48 hr to induce
ciliogenesis, and then fixed and stained with antibodies for acetylated tubulin (green) and Arl13B (red) to mark cilia, g-tubulin (blue/inset) for centrioles, and DAPI
(blue) to mark DNA.
(legend continued on next page)
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of ciliary pathways including fibroblast growth factor receptor
(FGFR) and Hedgehog, or impairing ciliogenesis through down-
regulation of ciliary proteins can overcome resistance in all cell
lines studied. Thus, we have uncovered a role for cilia in cancer
that provides a rationale for targeting ciliogenesis as a broadly
applicable strategy to overcome drug resistance.
RESULTS
Ciliogenesis Is Upregulated in Isogenic Models of
Acquired Drug Resistance
The role of primary cilia in human cancer is ill defined. Given the
wide range of oncogenic proteins that are regulated by or local-
ized to cilia (Christensen et al., 2012; Lauth et al., 2010), we hy-
pothesized that changes in ciliogenesis could play a permissive
role in the emergence of drug resistance. First, we examined
EGFR-inhibitor resistance in the EGFR mutant non-small cell
lung carcinoma (NSCLC) cell lineHCC4006.Wechose thismodel
system because EGFR inhibitors are effective in the treatment of
EGFRmutant lung cancer patients, but resistance to these drugs
is inevitable (Tan et al., 2016). Furthermore, the mechanisms of
drug resistance are still unknown for a large number of these
patients. We examined ciliogenesis in these cells by staining for
acetylated tubulin, a marker for cilia, or Arl13B, a marker specific
for ciliary membranes (Caspary et al., 2007; Cevik et al., 2010).
Interestingly, whereas control HCC4006 cells completely lacked
primary cilia, erlotinib-resistant HCC4006 cells generated by
chronic exposure to erlotinib (Saafan et al., 2016) (Figures
S1A–S1D) showed robust staining for ciliary markers (Figure 1A).
We then asked whether changes in ciliogenesis could be seen
in additional models of drug resistance, where the primary target
was not EGFR. We examined ciliation in the EML4-ALK-fusion-
positive lung cancer cell line NCI-H2228 (which is highly sensitive
to the ALK inhibitor NVP-TAE684) and a drug-resistant derivative
generated through chronic NVP-TAE684 exposure. Remarkably,
NVP-TAE684 resistant NCI-H2228 cells showed increased cilia
frequency and cilia length (Figures 1C–1E).
Next, we assessed ciliation in the rhabdoid tumor cell line
A204 (which is exquisitely sensitive to the tyrosine kinase inhib-
itor dasatinib) and a dasatinib-resistant (DasR) subline generated(D and E) Quantification of ciliated cells (D) and cilia length (E) shown in (C). n = 300
for an unpaired t test. Note that primary cilia were shorter in parental cells comp
(F) Rhabdoid tumor A204 cells (left panel) or a dasatinib-resistant (DasR) subline (
(red), and with DAPI (blue).
(G) Quantification of fraction of ciliated cells for the experiment shown in (F) (n =
(H and I) Quantification of cilia length (H) (n = 150) and cilia fragmentation (I) (n = 150
and p < 0.011 for (I), unpaired t test. Note that DasR cells show increased cilia le
(J–L) Quantification of primary cilia length (J), cilia fragmentation (K), and percentag
dasatinib for 48 hr, and then serum starved in the presence (Das) or absence (
p < 0.0001 for (J) and (K), Tukey’s multiple-comparison test, statistical significan
A204/Das.
(M) A204 (left) or DasR (right) cells were serum starved to induce ciliogenesis, and
tubulin (green) for cilia, and DAPI for DNA (blue). Note that a-tubulin is present al
fragmentation in DasR cells (right).
(N) A204 (left) or DasR cells (right) were stained for Arl13B tomark ciliary membran
indicates cilia fragments marked by both acetylated tubulin and Arl13B in DasR
(O) 3D structured illumination images of A204 and DasR cilia; Arl13B is shown in
surrounds acetylated tubulin. Arrows indicate budding fragments in DasR cells t
3044 Cell Reports 23, 3042–3055, June 5, 2018through chronic drug exposure, which we recently characterized
(Wong et al., 2016; Vyse et al., 2018) (Figure S1E). Notably, we
found that compared to parental cells, DasR cells showed
increased cilia length and tip fragmentation (Figures 1F–1I).
These effects were neither acute nor transient, as short-term
treatment with dasatinib did not promote these changes, and
withdrawing dasatinib from DasR cells for several days did not
revert the effect (Figures 1J–1L).
The changes in ciliogenesis observed in drug-resistant cells
were seen in the absence (Figure 1) or presence of serum (Fig-
ure S2), suggesting they are independent of growth rates.
In total, we interrogated five isogenic models of acquired drug
resistance (Table 1), of which only one (PC-9 lung adenocarci-
noma cells) did not show alterations in cilia (Figure S2). In this
model, however, cells with acquired resistance to the irreversible
EGFR inhibitor afatinib showed a nearly complete biochemical
insensitivity to the drug, consistent with the presence of a
drug-binding-interfering mutation, a known and common mech-
anism of drug resistance (Wu et al., 2016). PC9 cells that were
made resistant to erlotinib exhibited drug-resistant mitogen-
activated protein kinase (MAPK) activity, which has also been
described as amechanism of acquired EGFR inhibitor resistance
in both PC9 cells and in lung cancer patients (de Bruin et al.,
2014).
A549 cells resistant to chemotherapeutic agents including
cisplatin and vinflunine also showed increased ciliogenesis
(Figures S2M–S2O). Thus, our models cover resistance to a
range of clinically relevant therapeutic agents in several isogenic
models. Table 1 summarizes the types of cilia changes identified
in all models examined.
Cilia-derived vesicles have been shown to have important
intercellular functions in tetrahymena and Chlamydomonas
(Wang and Barr, 2016;Wood et al., 2013). However, cilia-derived
fragments have not been described in cancer cells. We therefore
set out to characterize the nature of the observed cilia fragmen-
tation in drug-resistant cells by examining tubulin post-transla-
tional modifications. No major difference was observed in total
tubulin acetylation (Figure S3A) or detyrosination (Figure S3B).
Interestingly, we found that the extent of polyglutamylated
tubulin, a modification shown to regulate microtubule stabilityfor (D) and n = 150 for (E). Error bars represent SD. p < 0.02 (D) and p < 0.005 (E),
ared to the NVP-TAE684-resistant subline.
right panel) were stained with acetylated tubulin to mark cilia (green), g-tubulin
300).
) for the experiment shown in (F). Error bars represent the SD. p < 0.0007 for (H)
ngth and cilia fragmentation.
e of ciliated cells (L) for A204 or DasR cells grown with (Das) or without (DMEM)
DMEM) of dasatinib for 48 hr. n = 150 cilia. The error bars represent the SD.
ce calculated by comparing DasR/DMEM and DasR/Das to A204/DMEM and
then fixed and stained for a-tubulin (red) to mark all microtubules, acetylated
ong the entire cilium axoneme in both A204 and DasR cells and it follows cilia
es (red), acetylated tubulin (green), g-tubulin (blue/inset), and DAPI (blue). Arrow
cells.
red and acetylated tubulin in green. Note that, at this resolution, Arl13B signal
hat contain membrane around them, suggesting an active budding event.
Table 1. Cilia and Drug Resistance
Cell Lines Drug Resistance > Cilia Length > Ciliated Cells Figure
Acquired Resistance
A204 DasR 1 Dasatinib ✔ – Figures 1F–1I and S2A
A204 DasR 2 Dasatinib ✔ – Figure S2A
H2228 NVP-TAE ✔ ✔ Figures 1C–1E
HCC4006 Erlotinib ✔ ✔ Figures 1A and 1B
PC9 Afatinib Afatinib – – Figures S2K and S2L
PC9 Erlotinib Erlotinib – – Figures S2K and S2L
De Novo Resistance
A549 Trametinib ✔ ✔ Figures 5A, 5C, and 5D
H23 Trametinib ✔ ✔ Figures S5B–S5D
H1792 Trametinib – ✔ Figures S5E–S5G
Acquired Chemoresistance
A549 Cisplatin ✔ – Figures S2M–S2O
A549 Carboplatin – – Figures S2M–S2O
A549 Vinflunine ✔ ✔ Figures S2M–S2O
Summary of cilia changes observed in resistant cell lines.(O’Hagan et al., 2011), showed slightly reduced intensity per unit
length in DasR cells (Figure S3C).
Furthermore, staining with total a-tubulin together with acety-
lated tubulin clearly showed a discontinuous axonemal pattern
in DasR cells compared to control cells (Figure 1M). These frag-
ments were positive for the cilia marker Arl13B (Figure 1N). In
fact, through super-resolution microscopy, we found that these
fragments were completely surrounded by Arl13B-containing
membrane (Figure 1O), suggesting that these are likely mem-
brane-bound fragmented pieces of cilia.
Cilia Length Control Is Involved in the Acquisition of
Drug Resistance
Next, we wanted to understand the molecular nature of the
longer cilia phenotype and whether cilia length could be respon-
sible for the observed changes in drug response. The kinesin
Kif7 has been shown to control cilia length by organizing
the cilia tip in coordination with the IFT-B particle IFT81 (He
et al., 2014). The changes in cilia length observed in DasR cells
were reminiscent of those seen in Kif7-deficient cells, suggest-
ing that Kif7 could be involved in this phenotype. In parental
A204 cells, we found that Kif7 localized to the ciliary base, along
the cilium, and at the cilium tip, as previously described (He
et al., 2014) (Figure 2A). In contrast, A204 DasR cells had a
significant decrease in Kif7 localization to the axoneme and cilia
tip (Figure 2A), while total Kif7 levels remained unchanged (Fig-
ure 2E). We also found that, in control A204 cells, IFT81 local-
ized along the axoneme and at the cilia tip. However, this was
significantly reduced in DasR cells (Figure 2B). The microtubule
plus-end-binding protein EB1, which localizes to centrioles and
cilia tips (Pedersen et al., 2003), is also thought to play a role in
cilia biogenesis (Schrøder et al., 2011). We found that the local-
ization of EB1 was restricted to centrioles in control A204 cells,
while in DasR cells EB1 localized along the ciliary axoneme as
well as the cilia tip (Figures 2C and 2D). Thus, control of cilialength and cilia tip compartment organization, as well as cilia
transport appear compromised in DasR cells. For the other
models presented in this study, the cilia length increase did
not correlate with defects in Kif7 localization (not shown). This
is likely due to differences in cellular and genetic context across
models, and argues that diverse molecular pathways might
drive resistance through their effects on ciliogenesis and/or cilia
length.
Kif7 inactivation has been shown to destabilize cilia (He et al.,
2014). Thus, we tested the stability of cilia in DasR cells by sub-
jecting them to cold treatment or the microtubule-destabilizing
agent nocodazole. Both treatments initially resulted in a signifi-
cantly increased rate of cilia shortening in DasR cells compared
to parental A204. However, by 60 min (30 min for nocodazole),
this difference in cilia length was no longer evident (Figures
S3D–S3G).
We reasoned that if cilia length was involved in drug resis-
tance, targeting cilia length control could modulate drug
response. Since Kif7 inactivation has been shown to increase
cilia length, we first downregulated Kif7 in parental A204
cells and assessed their response to dasatinib. Notably, Kif7-
depleted cells continued to grow in the presence of Dasatinib,
while control-transfected cells were growth arrested by the
inhibitor (Figure 2F). We observed a modest level of non-specific
transfection-induced toxicity in A204 cells. However, the overall
cell cycle profile of these cells was unaffected (Table S1). Kif7
depletion also caused the expected increase in cilia length
(Figures 2G–2I). Thus, dasatinib resistance in these cells seems
to involve misregulation of cilia length.
Kinase Inhibitor-Resistant Cells Show Increased
Hedgehog Pathway Activation
Because drug resistance often involves aberrant activation
of compensatory pathways (many of which reside in or are
controlled by cilia), we hypothesized that the observed changesCell Reports 23, 3042–3055, June 5, 2018 3045
Figure 2. Cilia Length Control Is Critical for the Acquisition of Resistance
(A) A204 (left panels) or DasR cells (right panels) were serum starved for 48 hr to induce ciliogenesis. After fixation, cells were stained with antibodies against
acetylated tubulin (green), Kif7 (red), and with DAPI (DNA, blue). Kif7 staining along the length of the cilia was quantified as shown. Error bars (n = 150) represent
SD. Kif7 p values (unpaired t test), proximal to distal: < 0.02 < 0.01, < 0.02, < 0.03, < 0.03, < 0.03, < 0.03, < 0.03, < 0.03, and < 0.02.
(B) A204 (left panels) and DasR cells (right panels) treated as in (A), were stained with antibodies for acetylated tubulin (green), IFT81 (red), and with DAPI
(blue). IFT81 staining along the length of the cilia was quantified as shown. Error bars (n = 150) represent SD. IFT81 p values (unpaired t test), proximal to
distal: < 0.03, < 0.02, < 0.001, < 0.02, and < 0.04. Note that both Kif7 and IFT81 are present along the cilia and at the cilia tip in control A204 cells (arrows) but are
absent in DasR cells.
(legend continued on next page)
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in cilia would lead to misregulated cilia-dependent signaling.
Activation of the evolutionarily conserved Hedgehog (Hh)
pathway requires a functional cilium, and it is coordinately regu-
lated at the body of the cilium and the cilium tip (Goetz et al.,
2009; Huangfu and Anderson, 2005). Given that changes in cilia
tip organization, KIF7 defects, and changes in ciliogenesis have
been shown to disrupt the Hedgehog pathway (He et al., 2014),
we hypothesized that cilia changes in resistant cells might affect
Hh function. We first examined SMO recruitment to the cilium
following SHH pathway stimulation (Figure 3A). Fluorescence
intensity quantification showed increased SMO recruitment to
cilia in DasR cells compared to control cells (Figures 3A, 3B,
S4A, and S4B). To assess the functional relevance of this in-
crease, we examined transcriptional targets of Hh activation by
RT-PCR at steady state and at different time points after addition
of human SHH. We found significantly higher induction of the Hh
target genes GLI1 and PTCH1 in response to either SHH (Figures
3C and 3D) or the SMO agonist (SAG) (Figures S4C and S4D) in
DasR cells compared to A204 control cells, thereby confirming
that the longer cilia observed in DasR cells support enhanced
Hh pathway activation (Figures 3A–3D and S4A–S4D). Consis-
tently, lung cancer H2228 cells with acquired resistance to the
ALK inhibitor NVP-TAE684 also showed increased Hedgehog
pathway activation (seen as both a significant increase in ciliary
localization of SMO following receptor engagement [Figures 3E
and 3F], and an increase in the levels of GLI1 ([Figure 3G])
compared to parental cells. Additionally, we observed an in-
crease in GLI2 levels in erlotinib-resistant HCC4006 cells
compared to parental controls (Figure 3H).
Cilia and Ciliary Pathways Are Important Mediators of
Kinase Inhibitor Resistance
Our results indicate that acquired resistance to kinase inhibitors
is associated with the upregulation of a number of ciliogenesis
pathways, and suggest that targeting cilia might be an effective
strategy to overcome resistance. To test this hypothesis, we
asked whether inhibition of ciliogenesis via knockdown of the
centriole distal appendage protein SCLT1 (Tanos et al., 2013)
or the IFT-B particle IFT88 (Pazour et al., 2000) could affect
KIR cell viability. While disrupting ciliogenesis in our three
models of acquired drug resistance had negligible effects in
cell cycle distribution (Table S1), it sensitized drug-resistant cells
to the appropriate kinase inhibitor (i.e., erlotinib, dasatinib,
or NVP-TAE684) (Figures 4A, 4E, and 4K). Furthermore, IFT88
knockdown in DasR cells significantly reduced anchorage-inde-(C) A204 cells (left panels) or DasR (right panels) were stained with acetylated tubu
at the cilia tip of DasR cells (arrow/inset) but not in parental A204 cells. Quantificat
distal: < 0.02, < 0.002, < 0.03, < 0.02, < 0.005, and < 0.006, for an unpaired t tes
(D) EB1was visually confirmed at the cilia tip of A204 andDasR cells. Chart shows
(E) Western blots showing total protein levels of Kif7, IFT81, and EB1 (upper pan
(F) Cell viability (CellTiter-Glo) of A204 cells grown in the presence of vehicle (DM
or Kif7 siRNA (as indicated). Cell viability was normalized to DMSO-treated cells (
p < 0.0001 (1 mM), unpaired t test.
(G) A204 cells were serum starved for 48 hr to induce ciliogenesis, and then fixed a
DAPI (blue). Note that A204 cells transfected with a Kif7 siRNA (siKif7) had incre
(H) Quantification of cilia length shown in (G). Cilia length in A204 cells transfected
represent SD. p < 0.002, for an unpaired t test.
(I) Western blot showing Kif7 levels in A204 cells transfected with control siRNApendent growth (Figure 4F) and increased apoptosis in the pres-
ence of the inhibitor (Figure 4G).
Drug resistance has been associated with entry of tumor cells
into a quiescent state (Sharma et al., 2010; Yeh and Ramasw-
amy, 2015). However, we did not observe any changes in the
G0/G1 fraction in any of the models we studied (Table S1).
Next, we interrogated the impact of pharmacological targeting
of cilia function on drug resistance. First, we focused on the Hh
pathway because it is upregulated in DasR cells and because
it has previously been implicated in drug resistance (Fai~ao-Flores
et al., 2017). Interestingly, we found that treatment with GANT61,
a small-molecule inhibitor of the Hh pathway (Lauth et al., 2007),
reduced viability in both DasR and control cells (Figure S4E),
highlighting the overall importance of the Hedgehog pathway
in certain cancers. Notably, treatment with the Gli inhibitor
GANT61 or the Smoothened inhibitor vismodegib significantly
sensitized resistant cells to the relevant kinase inhibitor (Figures
S4G, S4H, and S4J). Second, we targeted the FGFR because
it has been previously shown to control ciliogenesis and cilia
length (Neugebauer et al., 2009). We found that treatment of
erlotinib-resistant HCC4006 cells with the specific FGFR inhibi-
tor BGJ398 significantly reduced cilia formation (Figure 4N),
and more importantly, it re-sensitized these cells to erlotinib
(Figure 4P). We found similar results when we evaluated FGFR
inhibition in A204 DasR cells (Figures 4Q–4S) and NVP-
TAE684-resistant NCI-H2228 cells (Figures 4T–4U), suggesting
that inhibition of cilia regulators such as FGFR may represent
a good therapeutic strategy to overcome drug resistance in a
variety of contexts.
De Novo Drug Resistance Is Also Associated with
Increased Ciliogenesis
Finally, we wanted to know whether cilia changes were associ-
ated with any instances of de novo drug resistance. To address
this question, we used a previously described model of de novo
drug resistance in K-Ras mutant cells (Kitai et al., 2016; Man-
chado et al., 2016). Because direct targeting of Ras has been
challenging, inhibiting components of the downstream MAPK
pathway, including mitogen-activated protein kinase kinase
(MEK) has been pursued as an alternative strategy. However,
KRAS mutant cells are largely refractory to these drugs. Two in-
dependent studies found that, in KRASmutant lung cancer cells,
FGFR can mediate adaptive resistance to the MEK inhibitor tra-
metinib (Kitai et al., 2016; Manchado et al., 2016). We therefore
hypothesized that MEK-inhibitor resistance in KRAS mutantlin to mark cilia (green), EB1 (red), andwith DAPI (blue). Note that EB1 is present
ion of EB1 is shown. n = 150. Error bars represent SD. EB1 p values, proximal to
t.
quantification. n = 150. Error bars represent SD. p < 0.006, for an unpaired t test.
els, indicated) and loading controls (lower panels) in A204 and DasR cells.
SO) or dasatinib (doses are indicated), transfected with either control siRNA
n = 4). Error bars represent SD. p < 0.02 (0.125 mM), p < 0.0001 (0.25 mM), and
nd stained with antibodies for acetylated tubulin (green) and Kif7 (red), and with
ased cilia length compared to cells treated with a control siRNA (siCONT).
with siKif7 was significantly increased compared to siCONT. n = 150. Error bars
or Kif7 siRNA (indicated) for experiments shown in (F)–(H).
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Figure 3. Kinase Inhibitor-Resistant Cells Show Increased Hedgehog Pathway Activation
(A) A204 cells (top panels) or a dasatinib-resistant subline (DasR) (bottom panels) were serum starved for 24 hr, and then either left untreated (left) or treated with
human Sonic Hedgehog (SHH) (5 mg/mL) (right) for an additional 48 hr. Cells were then fixed and stained for acetylated tubulin to mark cilia (green), Smoothened
(SMO) (red), and with DAPI (blue). DasR cells show increased SMO localization to cilia compared to control A204 cells.
(B) Quantification of SMO cilia fluorescence intensities for the experiment shown in (A). Fluorescence intensity was normalized to surrounding fluorescence.
n = 150. Error bars represent SD. p < 0.01, for an unpaired t test.
(C and D) qPCR showing mRNA levels of Hh target genes of GLI1 (C) and PTCH1 (D) in A204 and DasR cells before serum starvation, after 24 hr of serum
starvation and after stimulation with 5 mg/mL SHH for the times indicated. TATA box-binding protein (TBP) was used as a reference gene, and fold change was
calculated by comparing mRNA levels relative to control (serum).
(E) NCI-H2228 parental or a NVP-TAE684 -resistant subline (NVP-TAE) was serum starved for 24 hr, and then either left in serum-freemedia or treated with human
SAG (100 nM) for an additional 48 hr. Cells were then fixed and stained for acetylated tubulin to mark cilia (green), Smoothened (SMO) (red), and with DAPI (blue).
NVP-TAE684-resistant cells show increased SMO localization to cilia compared to parental cells.
(F) Quantification of SMO cilia fluorescence intensities for the experiment shown in (E). Fluorescence intensity was normalized to surrounding fluorescence.
n = 150. Error bars represent SD. p < 0.0001 (parental SAG versus NVP-TAE684 SAG), p < 0.004 (parental SAG versus NVP-TAE684 control), and p < 0.0001
(NVP-TAE684 control versus NVP-TAE684 SAG), for Tukey’s multiple-comparison test.
(legend continued on next page)
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A549 cells would be accompanied by changes in ciliogenesis.
We found that cilia number as well as cilia length were upre-
gulated in A549 cells following trametinib treatment (Figures
5A–5E), although changes in Hedgehog pathway activation
were difficult to assess due to the significantly high level of basal
activity (Figures S5J–S5K). Additionally, KRAS mutant NCI-
H1792 and NCI-H23 lung cancer cells also showed upregulated
ciliogenesis and increased Hedgehog pathway activation (Fig-
ures S5A–S5I and S5K; Table 1) in response to MEK inhibition.
Furthermore, after 24 hr of drug treatment, the elongated cilia
in A549 cells started to show evidence of fragmentation (Figures
5A and 5E). Thus, these results suggest that release of terminal
cilia fragments might be a common feature of KIR cells indepen-
dently of the molecular identity of the resistance pathway.
Importantly, inhibiting ciliogenesis in all three KRAS mutant
lines reduced their viability when combined with trametinib (Fig-
ures 5F, S6A, and S6D), while having no significant changes in
cell cycle distribution on its own (Table S1). Furthermore, phar-
macological suppression of ciliogenesis via treatment with the
FGFR inhibitor BGJ398 significantly reduced the viability of these
cells in the presence of trametinib (Figures 5K, S6K, and S6O),
providing a potential mechanism for the previously described
synergistic effects of combined MEK and FGFR inhibitor treat-
ment in these cells (Kitai et al., 2016; Manchado et al., 2016).
In contrast, promoting cilia lengthening via Kif7 knockdown
(Figures 5L and 5N) significantly right-shifted the response to
trametinib in A549 cells (Figure 5M). These data strongly suggest
that similar to our models of acquired kinase inhibitor resis-
tance, changes in ciliogenesis can also mediate de novo adap-
tive resistance.
These data support a model wherein inhibition of certain ki-
nases leads to increasedactivationof FGFR (or other cilia promot-
ing pathways), leading to enhanced ciliogenesis and concomitant
Hedgehog pathway activation, thus facilitating the generation of
inhibitor insensitive survival signals (Figure 5O). Cilia could thus
function as a permissive platform for a number of drug resistance
mechanisms with broad therapeutic implications.
DISCUSSION
Our work suggests that ciliogenesis and cilia function as key
biological processes that play permissive roles in the emergence
of resistance to kinase inhibitors in cancer cells. Cilia have
been shown to have opposing roles in tumorigenesis, depending
on the nature of the driver oncogenic lesion (Han et al., 2009;
Wong et al., 2009). Our data show that resistance to a variety
of targeted therapies in several experimental models is charac-
terized by an increase in the number and/or length of primary
cilia and by cilia fragmentation. The latter is associated with
decreased cilia polyglutamylation, a modification known to
destabilize microtubules, which could contribute to cilia frag-
mentation. It is not clear how changes in the polyglutamylated(G)Western blot showing GLI1 levels in NCI-H2228 parental cells and the NVP-TA
serum-free media or treated with human SAG (100 nM) for an additional 48 hr. No
parental cells.
(H) Western blot showing Gli2 levels in HCC4006 parental cells and the ErloR-res
free media or treated with human SAG (100 nM) for an additional 48 hr. Note thefraction of cilia would influence drug response. However, it
has been shown that changes in polyglutamylation can bias
the recruitment of specific proteins to a-tubulin through its ef-
fects on the binding affinity of select motor proteins (Ikegami
et al., 2007), which could potentially affect cilia-directed survival
signaling.
Consistent with the notion that aberrant cilia can alter onco-
genic signaling, we find that the local abundance of a number
of cilia-associated oncoproteins changes in resistant cells.
For example, DasR cells lose PDGFRa expression (Figure S1F)
(Wong et al., 2016), show a slight increase in FGFR1 (Fig-
ure S1G), and have increased ciliary localization of IGF-1R
(Figures S1H–S1I).
We find that defects in cilia length control are involved in the
regulation of cilia-dependent drug resistance. One mechanism
of cilia elongation leading to drug resistance involves a decrease
in Kif7/IFT81 localization to cilia. In parental A204 cells, we find
that Kif7 is at the cilia tip, where it promotes microtubule plus-
end catastrophe, thus creating a tip compartment for the enrich-
ment of IFT81 (He et al., 2014). In contrast, in DasR cells, the
Kif7-rich cilia tip compartment is lost, which explains the
absence of IFT81. Additionally, we observed increased EB1
localization along the cilia and cilia tips in KIR cells (Figures 2C
and 2D), which is suggestive of defective diffusion barrier con-
trol. Thus, KIR cells have clearly defined molecular changes at
the cilia tips. These data raised the question of whether aberrant
cilia lengthening might be sufficient to confer drug resistance.
Notably, increasing cilia length through downregulation of Kif7
in either A204 or A549 cells did in fact promote resistance to
dasatinib and trametinib, respectively (Figures 2F and 5M).
Our results show that KIR cells have an enhanced response to
Hedgehog pathway activation (Figures 3, S4, and S5). Interest-
ingly, treatment of resistant cells with the Gli-selective inhibitor
GANT61 or the clinical SMO inhibitor vismodegib re-sensitized
these cells to the relevant kinase inhibitor (Figures S4G, S4H,
S4J, S5L, and S5M), suggesting that drug resistance may be
mediated by a critical effector of cilia-dependent signaling.
Interestingly, we and others have shown that resistance to
both the MEK inhibitor trametinib and the tyrosine kinase inhibi-
tor dasatinib can be mediated by activation of FGFR (Manchado
et al., 2016; Kitai et al., 2016; Wong et al., 2016) (Figure 5B), a
kinase known to regulate cilia length (Neugebauer et al., 2009).
Notably, we found that treatment of KIR cells with an FGFR inhib-
itor not only restored kinase inhibitor sensitivity (Figures 4P, 4S,
4U, 5K, and S6) but also reduced cilia and/or cilia length (Figures
4N, 4Q, 5I, and S6). Similarly, targeting ciliogenesis through
knockdown of the centriole distal appendage protein SCLT1
(Tanos et al., 2013) or the IFT particle IFT88 (Pazour et al.,
2000) sensitized cells to the relevant kinase inhibitor (Figures
4A, 4E, 4K, 5F, and S6).
This is in contrast to the lack of sensitizing activity of therapeu-
tic agents that cause growth arrest in specific phases of the cellE684-resistant subline. Cells were serum starved for 24 hr, and then either left in
te the increased expression of Gli1 in NVP-TAE684-resistant cells compared to
istant subline. Cells were serum starved for 24 hr, and then either left in serum-
increased levels of Gli2 in ErloR-resistant cells compared to parental cells.
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Figure 4. Cilia and Ciliary Pathways Are Important Mediators of Kinase Inhibitor Resistance
(A) Cell viability (CellTiter-Glo) in HCC4006 cells grown in erlotinib (indicated) were transfectedwith either control siRNA, IFT88 siRNA, or SCLT1 siRNA (indicated).
Cell viability was normalized to siCONT DMSO control (0 mM)-treated cells (n = 3). Error bars represent SD. p < 0.05 (siControl compared to siIFT88 at 0 mM),
p < 0.0001 (siControl versus siSCLT1 at 0 mM), p < 0.0008 (siControl versus siSCLT1 at 0.5 mM), p < 0.006 (siControl compared to siIFT88 at 1 mM), and p < 0.0007
(siControl versus siSCLT1 at 1 mM), Tukey’s multiple-comparison test.
(legend continued on next page)
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cycle (e.g., cisplatin, rapamycin, or doxorubicin), which suggests
that the sensitizing effects of ciliogenesis inhibition in drug-resis-
tant cells are unlikely to be attributed to cell cycle deregulation
(Figure S7). It is also unlikely that drug resistance-associated
changes in cilia are caused by alterations in cell cycle-dependent
signals (Plotnikova et al., 2009), given that drug-resistant cells
did not show any significant differences in cell cycle distribution
compared to their parental counterparts (Table S1).
Because cilia can extend during G0, and quiescence has been
associated with drug resistance, we examined the kinetics of cell
cycle re-entry in our isogenic models following serum starvation
and re-challenge. However, we did not find any correlation be-
tween time to re-entry and the observed changes in cilia, sug-
gesting quiescence is unlikely to be the cause of aberrant cilia-
tion or drug resistance in our models (Table S2).
Of note, we have also examined ciliation in an A549 isogenic
model of acquired chemoresistance and found that resistance
to cisplatin and vinflunine is also associated with a significant
increase in ciliogenesis (Figures S2M–S2O; Table 1), suggesting(B) Cilia quantification in HCC4006-erlotinib-resistant subline (ErloR) transfected w
(siSCLT1) (Smartpool). Note that, in both cases, cilia frequency is significantly dec
(siCONT versus siIFT88) and p < 0.005 (siCONT versus siSCLT1).
(C and D) Western blots showing IFT88 (C) or SCLT1 (D) levels in ErloR cells, trans
experiments shown in (A) and (B).
(E) Cell viability in A204 cells, grown in the absence or the presence of dasatinib (in
(Robert et al., 2007). Cell viability is normalized to A204 DMSO control (0 mM) (n = 3
0.5 mM dasatinib and p < 0.006 for DasR siCONT compared to siIFT88, unpaired
(F) Soft agar colony formation in DasR cells transfected with control siRNA or siRN
t test; n = 3.
(G) Caspase 3/7 activity of DasR cells after treatment with dasatinib in contro
caspase 3/7 activity was normalized to siCONT (DMSO), n = 3, p < 0.003 (siCON
p < 0.006 (siIFT88, 0.5 mM, versus siIFT88, 1 mM), < 0.002 (siCONT, 0 mM, versu
multiple-comparison test.
(H and I) Quantification of percent ciliated cells (n = 300) (H) and cilia length (n = 150
or control siRNA (siCONT). Error bars represent SD. p < 0.04 for (H) and p < 0.00
(J) Western blot showing IFT88 levels in DasR cells transfected with control siRN
(K) Cell viability in NCI-H2228 NVP-TAE684-resistant cells (NVP-TAE) after trea
SCLT1 (siSCLT1). Cell viability was normalized to siCONT (DMSO). n = 3, p < 0.006
of cilia, NVP-TAE684-resistant cells become more sensitive to the inhibitor.
(L) Quantification of percent ciliated cells (n = 300) for the experiment shown in (
(M) Western blot showing SCLT1 levels in NCI-H2228 NVP-TAE684-resistant cell
(K) and (L).
(N) Quantification of ciliated cells (percent) for HCC40006 erlotinib-resistant cells
after treatment with BGJ398, cilia length was reduced. n = 150. Error bars repre
(O) Cell viability (CellTiter-Glo) of the HCC4006 erlotinib-resistant subline (ErloR) g
was normalized to DMSO control (n = 3). Error bars represent SD. p < 0.004 (0 co
Tukey’s multiple-comparison test.
(P) Cell viability (CellTiter-Glo) of ErloR grown in 1 mM erlotinib (Erlo), 300 nM B
reduced growth compared to erlotinib used as a single agent. Cell viability was n
unpaired t test.
(Q) Cilia length of A204 dasatinib-resistant cells (DasR) treated with or without BG
with BGJ398, cilia length in DasR cells was reduced. n = 150. Error bars represe
(R) Cell viability (CellTiter-Glo) of the A204 Das-resistant subline (DasR) grown in a
(n = 3). Error bars represent SD. p < 0.0001 (0 compared to 50 nM, BGJ398), p
1,000 nM), Tukey’s multiple-comparison test.
(S) Cell viability (CellTiter-Glo) of DasR cells treated with dasatinib (0.5 mM), the F
is normalized to the DMSO control. Error bars represent SD. p < 0.004 (BGJ ve
comparison test.
(T) Cell viability (CellTiter-Glo) of the H2228 NVP-TAE684-resistant subline (N
normalized to DMSO control (n = 3). Error bars represent SD. p < 0.0001 (0 com
(U) Cell viability (CellTiter-Glo) of NCI-H2228 NVP-TAE684-resistant cells treated w
to the DMSO control. Error bars represent SD. p < 0.002, for an unpaired t test.that cilia might be involved in resistance to a wide range of
therapeutic agents.
In summary, our study shows that aberrant ciliogenesis could
serve as a functional platform for a variety of cancer drug resis-
tance mechanisms (both de novo and acquired) and provides
rationale for a broad therapeutic strategy to overcome resis-
tance in a variety of settings.EXPERIMENTAL PROCEDURES
Cell Culture
Cells were maintained in DMEM (A549, A204, and the dasatinib-resistant sub-
line DasR), andDME/F12 (HCC4006) containing 10% fetal bovine serum (FBS),
4 mM GlutaMax (Thermo Scientific, Waltham, MA), 500 mg/mL Normocin
(InvivoGen, San Diego, CA), 100 units/mL penicillin, and 100 mg/mL strepto-
mycin (Thermo Scientific). 5 mMdasatinib (LC Labs, Woburn, MA) was supple-
mented to DasR growth media. The erlotinib-resistant HCC4006 subline
was grown in the presence of 1 mM erlotinib (LC Labs). NCI-H23 and NCI-
H1792 were maintained in RPMI containing 10% FBS, 2 mM GlutaMax
(Thermo Scientific), 500 mg/mL Normocin (InvivoGen), 100 units/mL penicillin,ith either control siRNA, siRNA for IFT88 (siIFT88) (Smartpool), or SCLT1 siRNA
reased compared to control siRNA. n = 300. Error bars represent SD. p < 0.003
fected with control siRNA and either IFT88 siRNA (C) or SCLT1 siRNA (D) for the
dicated), and in DasR cells, after transfection with control siRNA or IFT88 siRNA
). Error bars represent SD. p < 0.005 for A204 grown in 0 dasatinib compared to
t test.
A for IFT88 (Robert et al., 2007). Error bar bars represent SD. p < 0.03, unpaired
l cells (siCONT) or upon downregulation of IFT88 (siIFT88). Fold change in
T 0 mM versus siCONT, 0.5 mM), < 0.002 (siIFT88 0 mM versus siIFT88, 0.5 mM),
s siCONT, 1 mM), and < 0.0001 (siIFT88, 0 mM, versus siIFT88, 1 mM), Tukey’s
) (I) for DasR cells transfected with an IFT88 siRNA (siIFT88) (Robert et al., 2007)
08 for (I), unpaired t test.
A or IFT88 siRNA (indicated) for experiments shown in (E)–(I).
tment with NVP-TAE684 in control cells (siCONT) or upon downregulation of
for 0.25 mM, and p < 0.006 for 0.5 mM, unpaired t test. Note that, in the absence
K). Error bars represent SD. p < 0.0003, unpaired t test.
s transfected with siCONT or siSCLT1 (indicated) for the experiments shown in
(ErloR) treated with or without the FGFR inhibitor BGJ398 for 72 hr. Note that,
sent SD. p < 0.04, unpaired t test.
rown in a range of concentrations for the FGFR inhibitor BGJ398. Cell viability
mpared to 50 nM, BGJ398) and p < 0.0004 (0 compared to 1,200 nM BGJ398),
GJ398, or both. Note that combining both erlotinib and BGJ398 significantly
ormalized to DMSO control (n = 3). Error bars represent SD. p < 0.0001, for an
J398 for 24 hr in reduced serum conditions (5% FBS). Note that, after treatment
nt SD. p < 0.0005, unpaired t test.
range of BGJ398 concentrations. Cell viability was normalized to DMSO control
< 0.003 (50 nM compared to 1,000 nM), and p < 0.03 (100 nM compared to
GFR1 inhibitor BGJ398 (100 nM), or a combination of both. n = 3. Cell viability
rsus BGJ + Das) and p < 0.0001 (Das versus BGJ + Das), Tukey’s multiple-
VP-TAE684) grown in a range of BGJ398 concentrations. Cell viability was
pared to 50, 100, and 900 nM, BGJ398), Tukey’s multiple-comparison test.
ith NVP-TAE684 (0.5 mM), BGJ398 (1.2 mM), or both. Cell viability is normalized
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Figure 5. De Novo Drug Resistance Is Associated with Increased Ciliogenesis and Ciliary Signaling
(A) A549 cells were treated with 50 nmol/L trametinib (Tram) or DMSO (vehicle control) for the indicated times, and then fixed and stained with antibodies for
acetylated tubulin (green), Arl13B (red), g-tubulin (blue/inset), and DAPI (blue). Note that exposure to trametinib promoted a significant increase in cilia, cilia length,
and fragmentation.
(B) Western blot showing levels of phosphorylated ERK, total ERK, vinculin (loading control), phospho-FRS2, and a-tubulin (loading control) in the presence and
absence of 50 nM trametinib (Tram) in A549 cells. Note that, after 48 and 72 hr of trametinib exposure, pERK was reduced. Phospho-FRS2 levels increased after
72 hr of trametinib treatment.
(C–E) Quantification of ciliated cells (C), cilia length (D), and fragmentation (E) for cells shown in (A). n = 150 cilia. Error bars represent the SD. p < 0.05 unpaired
t test.
(legend continued on next page)
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and 100mg/mL streptomycin (Thermo Scientific). NCI-H2228, PC9, A549, and
the cisplatin, carboplatin, and vinflunine-resistant sublines were maintained in
Iscove’s modified Dulbecco’s medium (IMDM) containing 10% FBS, 2 mM
GlutaMax (Thermo Scientific), 500 mg/mL Normocin (InvivoGen), 100 units/
mL penicillin, and 100 mg/mL streptomycin (Thermo Scientific). The NVP-
TAE684-resistant NCI-H2228 subline was supplemented with 0.5 mM NVP-
TAE684 (Axon Medchem; catalog #Axon 1416). PC9-resistant sublines were
cultured with 2 mM afatinib (Stratech Scientific; catalog #S1011-SEL) and
10 mM erlotinib (LC Labs). A549-chemoresistant sublines were cultured in
2 mg/mL cisplatin (Cayman Chemical Company, Ann Arbor, MI) or 10 mg/mL
carboplatin (Cayman Chemical Company). HEK293T cells were maintained
with DMEM containing 10% FBS, 2 mM GlutaMax (Thermo Scientific), 100
units/mL penicillin, and 100 mg/mL streptomycin (Thermo Scientific).
Ciliogenesis Experiments
To induce cilia formation, cells were plated on to poly-lysine-coated coverslips
in 3.5-cm plates at 0.43 106 cells per well, allowed to attach for 24 hr, and then
serum starved for 48 hr. For A549, NCI-H23, and NCI-H1792, ciliogenesis ex-
periments were carried out in the presence of serum, since trametinib proved
to be toxic otherwise. To activate the Hedgehog pathway, cells were serum
starved for 24 hr prior to the addition of 5 mg/mL SHH-N (Peprotech, London,
UK) or 100 nM SAG (Millipore, Darmstadt, Germany). For cilia stability exper-
iments, cells were either incubated in 4C culture media or treated with 10 mM
nocodazole (Sigma-Aldrich, St. Louis, MO).
Immunofluorescence
Cells were fixed in 4% paraformaldehyde for 10 min at room temperature, for
the following antibodies: mouse anti-a-tubulin (1:200; YL1/2; Bio-Rad;
MCA77G), mouse anti-acetylated tubulin (1:2,000; 6-11B-1; Sigma; T7451),
rabbit anti-Arl13B (1:500; Proteintech; 17711-1-AP), mouse anti-EB1
(1:250; BD Biosciences; 5/EB1), mouse anti-centrin (1:500; 3E6; Abnova;
H00001070-M01), rabbit anti-detyrosinated a-tubulin (1:100; Abcam;
ab48389), rabbit anti-IGF-1Rb (1:250; C-20; Santa Cruz; sc-713), mouse
anti-polyglutamylated tubulin (1:200; GT335; Adipogen; AG-20B-0020), and
rabbit anti-SMO (a kind gift from Kathryn Anderson; 1:500). An additional fixa-
tion step of 20 min in cold methanol was used for rabbit anti-IFT88 (1:500;
Proteintech; 13967-1-AP) and mouse anti-g-tubulin (1:500; TU-30; Santa
Cruz; sc-51715). For antibodies against Kif7 (1:500; rabbit polyclonal; kind
gift from Kathryn Anderson’s lab) and rabbit anti-IFT81 (1:200; Proteintech;
11744-1-AP), cells were first permeabilized for 2 min in PTEM buffer (20 mM
PIPES [pH 6.8], 0.2% Triton X-100, 10 mM EGTA, and 1 mM MgCl2) followed
by fixation in cold methanol for 20 min. After fixation, cells were permeabilized
for 5 min in 0.1% Triton X-100 in PBS, then blocked with 3% (w/v) bovine
serum albumin in PBS and 0.1% Triton X-100 for 5 min. Primary antibodies
were diluted in blocking solution and incubated for 1 hr followed by three
washeswith PBS and 0.1%Triton X-100. After that, goat secondary antibodies(F) Cell viability in A549 cells after treatment with the MEK inhibitor trametinib in c
SCLT1 (siSCLT1). Cell viability was normalized to siCONTDMSO control (0 nM) ce
p < 0.003 for 12.5 nM, unpaired t test.
(G) A549 cells transfected with siRNA for SCLT1 (siSCLT1) had reduced ciliated
p < 0.0001.
(H) Western blot showing SCLT1 levels in A549 cells transfected with control siR
(I) Cilia quantification of A549 cells treated with or without the FGFR inhibitor BGJ3
cells was reduced. n = 150. Error bars represent SD. p < 0.003, unpaired t test.
(J) Cell viability (CellTiter-Glo) of A549 cells grown in a range of BGJ398 concentra
SD. p < 0.02, Tukey’s multiple-comparison test.
(K) Cell viability (CellTiter-Glo) of A549 cells treated with trametinib (6.25 nM), BGJ
DMSO control. Error bars represent SD. p < 0.02, for an unpaired t test.
(L) Quantification of cilia length (n = 150) of A549 cells transfected with control siR
(50 nM) for 48 hr. Error bars represent SD. p < 0.0009 (siCONT DMSO versus s
(siCONT DMSO versus siKif7 Tram), Tukey’s multiple-comparison test.
(M) Cell viability in A549 cells after treatment with trametinib in control cells (siCON
for both siCONT and siKif7. n = 4. p < 0.0006 for 6.25 nM and p < 0.01 for 12.5 n
(N) Western blot showing Kif7 levels in A549 cells transfected with control siRNA
(O) Proposed model for upregulation of ciliogenesis leading to kinase inhibitor reconjugated to either Alexa Fluor 488, 594, or 680 (1:500 dilution; Thermo Sci-
entific) were incubated for 1 hr followed by three washes and incubation with
DAPI (Thermo Scientific).
Image Acquisition and Analysis
Fluorescent images were acquired on an upright microscope (Axio Imager M2;
Zeiss) equippedwith 1003 oil objectives, 1.4 numerical aperture (N.A.), a cam-
era (ORCA R2; Hamamatsu Photonics), and a computer with image-process-
ing software (Zen). Images were quantified for pixel density and cilia length
using ImageJ and MATLAB and assembled into figures using Photoshop
(CS5; Adobe). For pixel density quantification, images were taken using equal
settings. ImageJ pixel density quantification measured the mean gray value
(sum of the gray values of all the pixels in the selection divided by the number
of pixels), of cilia defined by either Arl13b or acetylated tubulin staining.
For MATLAB quantifications, we used a custom-written script to quantify
fluorescent intensity profiles along cilia. Cilia were segmented in a user-inter-
active manner using the improfile function from MATLAB. Improfile retrieves
the intensity values of pixels along a multiline path defined by the user. Acet-
ylated tubulin or Arl13B was used to define the cilium path, and intensity pro-
files were retrieved from channels of interest. To reduce noise, we measured
the average fluorescent intensity of 3 pixels (above, on, and below the path)
for each position along the cilium. To compare intensity profiles along cilia of
different lengths, we divided cilium length into ten bins and extracted the
average fluorescent intensity for each bin. The script is available upon request.
3D structured illumination images were acquired using an SR1 Elyra PS1 mi-
croscope (Zeiss), images were processed using the ImageJ plugin SIMcheck
to remove artifacts, and 3D videos were made using the Volocity software
(PerkinElmer).
Western Blots
Cells were lysed in RIPA buffer (Sigma-Aldrich) supplemented with protease
and phosphatase inhibitors (Thermo Scientific) on ice. Lysates were sonicated
and cleared by centrifugation at 12,000 3 g at 4C for 30 min. Samples were
separated by SDS-PAGE on 3–8% polyacrylamide gradient gels followed by
transfer to nitrocellulose membranes. Membranes were probed with primary
antibodies against mouse anti-Erk (1:1,000; 3A7; Cell Signaling; 9107), rabbit
anti-phospho-Erk (1:1,000; Cell Signaling; 9101), rabbit anti-Met (1:1,000;
D1C2; Cell Signaling; 8198), rabbit anti-phospho-Met (1:1,000; D26; Cell
Signaling; 3077), rabbit anti-EGFR (1:1,000; D38B1; Cell Signaling; 4267), rab-
bit anti-phospho-EGFR (1:1,000; D7A5; Cell Signaling; 3777), rabbit anti-Gab1
(1:1,000; Cell Signaling; 3232), rabbit anti-phospho-Gab1 (1:1,000; C32H2;
Cell Signaling; 3233), mouse anti-GLI1 (1:750; L42B10; Cell Signaling; 2643),
rabbit anti-phospho-FRS2-a (1:500; Cell Signaling; 3864), rabbit anti-GLI2
(1:500; H-300; Santa Cruz; sc-28674), mouse anti-FLAG (1:1,000; M2; Sigma;
F1804), rabbit anti-IGF-1Rb (1:250; C-20; Santa Cruz; sc-713), rabbit anti-Kif7
(1:500), rabbit anti-SCLT1 (1:500; Sigma; HPA036560), mouse anti-b-Actinontrol cells (siCONT) or upon downregulation of the distal appendage protein
lls. n = 3, p < 0.0001 for 0 nM, p < 0.008 for 1.56 nM, p < 0.0009 for 6.25 nM, and
cells compared to siRNA control (siCONT). n = 300. Error bars represent SD.
NA or SCLT1 siRNA (indicated) for the experiments shown in (F) and (G).
98 for 48 hr. Note that, after treatment with BGJ398, the percentage of ciliated
tions. Cell viability was normalized to DMSO control (n = 3). Error bars represent
398 (300 nM), or a combination of both. n = 3. Cell viability is normalized to the
NA (siCONT) or Kif7 siRNA (siKif7) and treated with either DMSO or trametinib
iCONT Tram), p < 0.004 (siCONT DMSO versus siKif7 DMSO), and p < 0.005
T) or upon downregulation of Kif7 (siKif7). Cell viability was normalized to 0 nM
M, unpaired t test.
(siCONT) or Kif7 siRNA (siKif7) for the experiment shown in (L) and (M).
sistance.
Cell Reports 23, 3042–3055, June 5, 2018 3053
(1:2,000; AC-74; Sigma; A5316), rabbit anti-PDGFRa (1:500; D1E1E; Cell
Signaling; 3174), rabbit anti-FGFR1 (1:1,000; Abcam; EPR806Y), rabbit anti-
IFT81 (1:500; Proteintech; 11744-1-AP), mouse anti-EB1 (1:500; BD Biosci-
ences; 5/EB1), rabbit anti-IFT88 (1:500; Proteintech; 13967-1-AP), mouse
anti-a-tubulin (1:1,000; 236-10501; A11126; Thermo Scientific), and mouse
anti-vinculin (1:2,000; hVIN-1; Sigma; V9131). Secondary antibodies were
horseradish peroxidase (HRP)-conjugated rabbit ormouse anti-IgG antibodies
(1:2,000; Cell Signaling).
Small Interfering RNA Gene Knockdown
Small interfering RNA (siRNA)-mediated IFT88 knockdown was carried
out using two pooled sequences, 50-CGACUAAGUGCCAGACUCAUU-30 and
50-CCGAAGCACUUAACACUUA-30, previously described (Robert et al., 2007),
when indicated, or a SMARTpool ON-TARGETplus siRNA (GE Dharmacon,
Lafayette,CO). SCLT1knockdownwasachievedusinga siGENOMESmartpool
siRNA (GE Dharmacon). Kif7 was downregulated using a SMARTpool ON-
TARGETplus siRNA (GE Dharmacon). Cells were transfected with Lullaby
(Oz Biosciences, San Diego, CA) (three sequential transfections) or Lipofect-
amine RNAimax for the Smartpool (two sequential transfections). Non-targeting
(control) siRNA was purchased from QIAGEN (#1027281).
Plasmids and Transfections
The human full-length FLAG-Kif7 construct was a kind gift fromDr.Max Liebau
(University of Cologne, Cologne, Germany). Cells were transfected with Lipo-
fectamine 3000 (Thermo Scientific).
All lentiviruses were generated by transient co-transfection of 293T cells
with packaging and envelope vectors using polyethylenimine (PEI) from
Polysciences as a transfection reagent. The TRIPZ inducible human shIFT88
plasmid (GE Dharmacon) was used for stable IFT88 gene knockdown. H23
cells were selected for using 2 mg/mL puromycin.
Cell Viability Assays
4,000 cells/well (2,000 cells/well for A204/DasR) were seeded into a 96-well
plate (Greiner Bio-One, Kremsmunster, Austria) and incubated for 24 hr at
37C, 5% CO2. After that, medium (5% FBS) containing drugs or vehicle con-
trols was added to the cells and incubated for an additional 72 hr. Cell viability
wasmeasured using CellTiter-Glo (Promega), using a Victor X5 2030Multilabel
plate reader (Perkin Elmer). Cisplatin was obtained from Cayman Chemical
Company, doxorubicin from LC Labs, and rapamycin from Calbiochem
(San Diego, CA, USA). Additional growth assays were carried out using a ViCell
Cell Viability Analyzer (Beckman Coulter). Briefly, 125,000 cells were seeded
on 60-mm dishes in media containing 10% FCS. Cells were treated for
3–5 days with different drug concentrations in media containing no serum.
Following treatment, viability was assessed using the trypan blue exclusion
method. Each condition has been measured in triplicate.
Caspase 3/7 Assay
4,000 cells/well were seeded into a 96-well plate (Greiner Bio-One, Krems-
munster, Austria) and incubated for 24 hr at 37C, 5%CO2. After that, medium
(5% FBS) containing drugs or vehicle controls was added to the cells and
incubated for an additional 48 hr. Caspase 3/7 activity was measured using
Caspase 3/7 Glo (Promega), with a Victor X5 2030 Multilabel plate reader (Per-
kin Elmer).
Cell Cycle Analysis
To determine the cell cycle distribution, DNA content was assessed using pro-
pidium iodide (PI) staining. Cells were trypsinized and fixed in ice-cold 70%
ethanol, and then stained with 20 mg/mL PI and 100 mg/mL RNAase A for
30 min. Samples were run using a BD LSR II flow cytometer (BD Biosciences)
and FlowJo to analyze results.
Hedgehog Pathway qRT-PCR
RNA was extracted using RNA mini kit (Thermo Scientific). Primers and
TaqMan probes for detection of human Tata binding protein (TBP), GLI1,
and PTCH1 were purchased as Assays-on-Demand from Applied Biosystems
(TBP, Hs00427620_m1; GLI1, Hs01110766_m1; PTCH1, Hs00181117_m1).
SuperScript III Platinum One-Step qRT-PCR System (Invitrogen) was used3054 Cell Reports 23, 3042–3055, June 5, 2018for the qPCR (PCR protocol: 15 min 50C, 2 min 95C, 30–503 15 s 95C
and 1 min 60C). The amount of amplicon generated during the PCR was
measured using a QuantStudio 6 Flex Real-Time PCR System (Applied
Biosystems). Each sample was run in triplicate; controls without reverse
transcriptase gave no signal in all samples.
Soft Agar Assay
Eachwell of a six-well dishwas coatedwith 1mL of base layer containing 0.6%
agar (Sigma-Aldrich). Cells were dissociated and filtered through 30-mm filter
and sub-cultured by layering 1 3 104 viable cells in 1.5 mL of culture medium
(5% FBS) containing 0.3% agar over replicate base layers. An upper layer of
2 mL of culture medium (5% FBS) was applied to each well and changed every
3 days. Colonies were counted using Gelcount (Oxford Optronix).
Statistical Tests
Statistical analyses and samples sizes are specified in the figure legends. The
error bars indicate either SD or SE (indicated).
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